| 期 |
栏目 |
标题 |
文件 |
| 卷 15, 编号 1 (2013) |
Articles |
CUP-syndrome: the present view of the problem (a review of literature) |
|
| 卷 15, 编号 2 (2013) |
Articles |
Prognostic value of p53 expression in patients with stage I breast cancer |
|
| 卷 15, 编号 2 (2013) |
Articles |
Toxicity of trabectedin-based combinations in the treatment of different malignant tumors |
|
| 卷 15, 编号 3 (2013) |
Articles |
Prognosticheskoe znachenie lokal'nogo i sistemnogo lecheniya pri rake molochnoy zhelezy I stadii |
|
| 卷 15, 编号 3 (2013) |
Articles |
Rezul'taty «Epidemiologicheskoy programmy skrininga HER2-statusa u bol'nykh rakom molochnoy zhelezy» v Rossiyskoy Federatsii |
|
| 卷 15, 编号 4 (2013) |
Articles |
The efficiency of trabectedin in the monotherapy and combinations in the treatment of advanced ovarian cancer |
|
| 卷 15, 编号 4 (2013) |
Articles |
Bone mineral density in patient with breast cancer |
|
| 卷 16, 编号 1 (2014) |
Articles |
The Avastin application in clinical practice in patients with metastatic colorectal cancer: Second interim analysis of the observational AJAX program |
|
| 卷 16, 编号 4 (2014) |
Articles |
Modern possibilities of HER2 positive breast cancer treatment (based on clinical trials) |
|
| 卷 17, 编号 1 (2015) |
Articles |
Breast cancer immunology: theory and prospects (review) |
|
| 卷 16, 编号 3 (2014) |
Articles |
Vulvar Langerhans cell histiocytosis: case report |
|
| 卷 17, 编号 1 (2015) |
Articles |
A population-based portrait of breast cancer in russia: a cancer register-based analysis in russian |
|
| 卷 17, 编号 1 (2015) |
Articles |
Immunological heterogeneity of stage I breast cancer:biological, population-based and prognostic value (international cooperation experience) |
|
| 卷 17, 编号 3 (2015) |
Articles |
The results of Epidemiological HER2 screening program in patients with breast cancer in 2014 |
|
| 卷 17, 编号 3 (2015) |
Articles |
Clinical and prognostic significance of matrix metalloproteinase-7 and vascular endothelium growth factor in patients with ovarian cancer |
|
| 卷 17, 编号 3 (2015) |
Articles |
Current understanding of the role of insulin-like and vascular endothelial growth factors in development, prognosis and targeted therapy in patients with ovarian cancer |
|
| 卷 18, 编号 1 (2016) |
Articles |
Features of surgical treatment of patients with breast cancer receiving preoperative systemic therapy |
(Rus)
|
| 卷 18, 编号 1 (2016) |
Articles |
Insulin-like growth factors in patients with ovarian tumors (results of own research) |
(Rus)
|
| 卷 19, 编号 4 (2017) |
Articles |
Clinical and radiological evaluation the effectiveness of preoperative systemic therapy in different biological subtypes of breast cancer stages T1-3N0-1M0 |
(Rus)
|
| 卷 19, 编号 3 (2017) |
Articles |
Dynamics of circulating tumor cells during neoadjuvant chemotherapy in patients with locally-advanced breast cancer |
(Rus)
|
| 卷 20, 编号 1 (2018) |
Articles |
Taxanes induced peripheral neuropathy: mechanism of development and pharmacogenetic factors |
(Rus)
|
| 卷 20, 编号 3 (2018) |
Articles |
The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer |
(Rus)
|
| 卷 20, 编号 4 (2018) |
Articles |
Quality control of immunohistochemical analyzes in Russia: yesterday, today, tomorrow |
(Rus)
|
| 卷 20, 编号 4 (2018) |
Articles |
Bendamustine in the treatment of B-cell non-Hodgkin lymphoma |
(Rus)
|
| 卷 21, 编号 2 (2019) |
Articles |
Successful experience of combined immunochemotherapy at refractory course of primary cutaneous peripheral T-cell lymphoma, unspecified |
(Rus)
|
| 卷 21, 编号 1 (2019) |
Articles |
Opportunities of the pharmacogenetic approach to personalized tamoxifen breast cancer therapy: case reports |
(Rus)
|
| 卷 21, 编号 1 (2019) |
Articles |
The potential use of oncolytic viruses in breast cancer: historical aspects and future prospects (literature review) |
(Rus)
|
| 卷 21, 编号 4 (2019) |
CLINICAL ONCOLOGY |
The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution |
(Rus)
|
| 卷 22, 编号 1 (2020) |
CLINICAL ONCOLOGY |
Solitary (extramedullary) plasmocytoma. Clinical recommendations |
(Rus)
|
| 卷 22, 编号 1 (2020) |
CLINICAL ONCOLOGY |
ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution |
(Rus)
|
| 卷 22, 编号 1 (2020) |
CLINICAL ONCOLOGY |
Modern view on the issues of diagnosis and verification of axillary lymph nodes involvement in early breast cancer |
(Rus)
|
| 卷 22, 编号 2 (2020) |
Guidelines |
Hodgkin's lymphoma |
(Rus)
|
| 卷 22, 编号 2 (2020) |
Guidelines |
Follicular lymphoma |
(Rus)
|
| 卷 22, 编号 2 (2020) |
Conference Proceedings |
Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic |
(Rus)
|
| 卷 22, 编号 2 (2020) |
Original Article |
Maintenance oncohematological patients and new coronavirus infection: experience of the City Clinical Hospital №52 |
(Rus)
|
| 卷 22, 编号 2 (2020) |
Conference Proceedings |
New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas |
(Rus)
|
| 卷 22, 编号 2 (2020) |
Review |
Accompanying therapy in oncohematological patients with secondary immunodeficiency |
(Rus)
|
| 卷 22, 编号 2 (2020) |
Best Practice |
Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience |
(Rus)
(Eng)
|
| 卷 22, 编号 2 (2020) |
Original Article |
First-line therapy of indolent non-Hodgkin’s lymphoma in routine clinical practice |
(Rus)
|
| 卷 22, 编号 4 (2020) |
CLINICAL ONCOLOGY |
Multiple myeloma |
(Rus)
|
| 卷 22, 编号 4 (2020) |
CLINICAL ONCOLOGY |
The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review |
(Rus)
|
| 卷 22, 编号 4 (2020) |
CLINICAL ONCOLOGY |
Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimia® BIOCAD (INN: empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy |
(Rus)
|
| 卷 23, 编号 1 (2021) |
CLINICAL ONCOLOGY |
Modern approaches in the first line treatment of CD30-positive peripheral T-cell lymphomas |
(Rus)
|
| 卷 23, 编号 2 (2021) |
CLINICAL ONCOLOGY |
Biological features of ductal carcinoma in situ: clinical role and basis for treatment individualization |
(Rus)
|
| 卷 23, 编号 3 (2021) |
CLINICAL ONCOLOGY |
Extrapulmonary small cell carcinoma. Literature review |
(Rus)
|
| 卷 23, 编号 2 (2021) |
CLINICAL ONCOLOGY |
The use of erythropoietins in oncology |
(Rus)
|
| 卷 23, 编号 4 (2021) |
CLINICAL ONCOLOGY |
Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III |
(Rus)
|
| 卷 24, 编号 1 (2022) |
CLINICAL ONCOLOGY |
Immuno-morphological characteristics of bone marrow in patients with ovarian cancer |
(Rus)
|
| 卷 24, 编号 1 (2022) |
CLINICAL ONCOLOGY |
Therapy of lymphoproliferative diseases in the era of COVID-19: challenges and solutions |
(Rus)
|
| 卷 24, 编号 1 (2022) |
CLINICAL ONCOLOGY |
From the editor-in-chief of the journal "Modern Oncology" Academician of the Russian Academy of Sciences I.V. Poddubnaya |
(Rus)
|
| 卷 24, 编号 1 (2022) |
CLINICAL ONCOLOGY |
Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases who receive cytotoxic therapy: results of LEGERITY, the second interim analysis of multicenter retrospective-and-prospective observational post-marketing study |
(Rus)
|
| 卷 24, 编号 3 (2022) |
CLINICAL ONCOLOGY |
Analysis of the complications of endocrine therapy with tamoxifen in breast cancer: clinical and pharmacogenetic aspects. Prospective pharmacogenetic cohort study |
(Rus)
|
| 卷 24, 编号 2 (2022) |
CLINICAL ONCOLOGY |
Risk of discrimination against Russian citizens in providing medical care abroad as a health care trend |
(Rus)
|
| 卷 24, 编号 3 (2022) |
CLINICAL ONCOLOGY |
The analysis of the relationship between transferrin receptor 1 (TfR1) and clinical, morphological and immunophenotypic characteristics of breast cancer: retrospective cohort study |
(Rus)
|
| 卷 24, 编号 3 (2022) |
CLINICAL ONCOLOGY |
Genetic markers associated with resistance to radioiodine therapy in thyroid cancer patients: Prospective cohort study |
(Rus)
|
| 卷 25, 编号 1 (2023) |
CLINICAL ONCOLOGY |
Clinical factors of the risk of hyperplastic endometry processes on tamoxifen therapy with breast cancer: Retrospective population study |
(Rus)
|
| 卷 25, 编号 2 (2023) |
CLINICAL ONCOLOGY |
Heterogeneous diffuse large B-cell lymphoma: accurate diagnosis as a key to successful therapy. A review |
(Rus)
|
| 卷 25, 编号 2 (2023) |
CLINICAL ONCOLOGY |
Challenges and perspectives of first-line therapy in patients with diffuse B-cell lymphoma: A review |
(Rus)
|
| 卷 25, 编号 2 (2023) |
CLINICAL ONCOLOGY |
Interrelation of HLA-I and class II major histocompatibility complex molecules with clinical and morphological signs of breast cancer: A retrospective cohort study |
(Rus)
|
| 卷 25, 编号 3 (2023) |
History of medicine |
Memorial lecture to the 100th anniversary of the birth of Professor Yu.I. Lorie |
(Rus)
|
| 卷 25, 编号 3 (2023) |
CLINICAL ONCOLOGY |
Diffuse large B-cell lymphoma: strokes to the epidemiological portrait. A review |
(Rus)
|
| 卷 25, 编号 3 (2023) |
CLINICAL ONCOLOGY |
An interdisciplinary approach to the management of oncohematological patients with immunodeficiency: clinical cases. A review |
(Rus)
|
| 卷 25, 编号 4 (2023) |
CLINICAL ONCOLOGY |
Can bispecific antibodies change the paradigm and goals of therapy for patients with relapsed non-Hodgkin lymphomas? |
(Rus)
|
| 卷 25, 编号 4 (2023) |
CLINICAL ONCOLOGY |
Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases receiving cytotoxic therapy: results of LEGERITY, a multicenter retrospective-and-prospective observational post-marketing study |
(Rus)
|
| 卷 26, 编号 2 (2024) |
Articles |
Immunohistochemical factors of prognosis of immunotherapy for metastatic melanoma: А prospective and retrospective study |
(Rus)
|
